Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01657942 · ClinicalTrials.gov registry record · NA
Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 101
- Enrollment target
NCT01657942 is a NA study that has completed, run by InSightec. The registered enrollment target is 101 participants.
The verdict
NCT01657942, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
Study Summary
The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated patients, as described above.
Interventions
- DEVICE ExAblate MR Guided Focused Ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-10 |
| Est. Completion | 2021-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01657942
The ClinicalTrials.gov registry entry for NCT01657942 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ExAblate MR Guided Focused Ultrasound is the first listed.
NCT01657942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01657942 about?
NCT01657942 is a clinical study titled "Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions". The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety a...
What is the current status of trial NCT01657942?
This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2013-10. Estimated completion is 2021-05.
What interventions are being tested in trial NCT01657942?
The interventions under investigation include: ExAblate MR Guided Focused Ultrasound (DEVICE).
Who is sponsoring clinical trial NCT01657942?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.